Saniona AB (publ) (SANION.ST)
SEK 8.05
(3.34%)
SEK 8.05
(3.34%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 71.4 Million SEK | -12.41% |
| 2022 | 81.52 Million SEK | -18.29% |
| 2021 | 99.77 Million SEK | 110.0% |
| 2020 | 47.51 Million SEK | 3245.85% |
| 2019 | 1.42 Million SEK | -76.33% |
| 2018 | 6 Million SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 66.75 Million SEK | -6.51% |
| 2024 Q2 | 70.34 Million SEK | 5.37% |
| 2023 Q3 | 67.31 Million SEK | -6.89% |
| 2023 FY | 71.4 Million SEK | -12.41% |
| 2023 Q1 | 81.09 Million SEK | -0.53% |
| 2023 Q4 | 71.4 Million SEK | 6.09% |
| 2023 Q2 | 72.29 Million SEK | -10.85% |
| 2022 Q1 | 98.68 Million SEK | -1.09% |
| 2022 Q3 | 81.97 Million SEK | -16.16% |
| 2022 Q4 | 81.52 Million SEK | -0.55% |
| 2022 FY | 81.52 Million SEK | -18.29% |
| 2022 Q2 | 97.76 Million SEK | -0.93% |
| 2021 Q4 | 99.77 Million SEK | -1.14% |
| 2021 FY | 99.77 Million SEK | 110.0% |
| 2021 Q3 | 100.91 Million SEK | 398.73% |
| 2021 Q2 | 20.23 Million SEK | -8.9% |
| 2021 Q1 | 22.21 Million SEK | -53.25% |
| 2020 Q4 | 47.51 Million SEK | -5.24% |
| 2020 Q1 | 26.32 Million SEK | 1753.59% |
| 2020 FY | 47.51 Million SEK | 3245.85% |
| 2020 Q2 | 35.05 Million SEK | 33.18% |
| 2020 Q3 | 50.13 Million SEK | 43.04% |
| 2019 Q4 | 1.42 Million SEK | -55.39% |
| 2019 FY | 1.42 Million SEK | -76.33% |
| 2019 Q1 | 10.9 Million SEK | 81.68% |
| 2019 Q2 | 13.43 Million SEK | 23.28% |
| 2019 Q3 | 3.18 Million SEK | -76.32% |
| 2018 Q3 | 1 Million SEK | -91.67% |
| 2018 FY | 6 Million SEK | 0.0% |
| 2018 Q4 | 6 Million SEK | 500.0% |
| 2018 Q1 | 10 Million SEK | 0.0% |
| 2018 Q2 | 12 Million SEK | 20.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 16.09 Million SEK | -343.617% |
| Ziccum AB (publ) | 857 Thousand SEK | -8232.439% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | -1334.204% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | -191.608% |
| Genovis AB (publ.) | 79.32 Million SEK | 9.974% |
| Intervacc AB (publ) | 181 Thousand SEK | -39352.486% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | -246.461% |
| Active Biotech AB (publ) | 3 Million SEK | -2280.3% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | -18.419% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -1328.18% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 7.82 Million SEK | -812.225% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -16741.745% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | 34.246% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -2226.026% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -2667.791% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -7040.9% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 92.707% |
| Camurus AB (publ) | 24.5 Million SEK | -191.382% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | -159.047% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 91.761% |
| Cyxone AB (publ) | 858 Thousand SEK | -8222.727% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -4073.524% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | -94.004% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -10622.072% |
| SynAct Pharma AB | 637 Thousand SEK | -11110.204% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -8301.059% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -3955.026% |
| BioInvent International AB (publ) | 23.24 Million SEK | -207.215% |
| Alzinova AB (publ) | 800 Thousand SEK | -8826.125% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 32.941% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -9136.948% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | 21.304% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | -132.815% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 69.151% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -6630.349% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |